Skip to main content
. 2018 Jun 4;23(11):1269–e125. doi: 10.1634/theoncologist.2018-0203

image

Serious adverse events possibly related to study treatment. Both events were considered to be possibly related to ziv‐aflibercept (unlikely to be related to ganetespib).

Abbreviation: NOS, not otherwise specified.